Research programme: interleukin inhibitors - RigelAlternative Names: R 256
Latest Information Update: 17 Nov 2014
At a glance
- Originator Rigel Pharmaceuticals
- Class Small molecules
- Mechanism of Action Interleukin 13 inhibitors; Interleukin 4 inhibitors; Janus kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Asthma